PRKDC and cancer: Interestingly, ectopic activation of the EGFR-DNA-PK cascade has also been closely linked to tumourigenesis and radio/chemo-resistance.49, 50, 51, 52, 53 Indeed, as a high proportion of malignancies feature hyperactivation/mutation of EGFR, the EGFR is a mainstay of anti-cancer research.25, 54, 55, 56 Similarly, DNA-PK-selective antagonists, including NU7441, are promising new anti-cancer drugs.51, 57 In this context, discovery of platelets as a potent, atypical and injury-specific activator of EGFR-DNA-PK signalling is of explicit relevance to the field of cancer.